Women’s health is undergoing a long-overdue transformation. For decades, underrepresentation in clinical research, chronic underfunding, and a narrow focus on reproductive health left vast areas of female biology overlooked. Diseases that disproportionately affect women — ranging from autoimmune disorders to chronic pain syndromes — have been historically under-researched, resulting in slower progress and fewer targeted therapies. Today, however, a convergence of factors is reshaping the landscape: rising investment in femtech, regulatory pushes for diversity in trials, and demographic shifts that are expanding demand for effective, women-centered care.
The 10 companies profiled here — Oviva Therapeutics, Gameto, Freya Biosciences, Comanche Biopharma, Gynica, Fab Biopharma, Aurinia Pharmaceuticals, Aclaris Therapeutics, Daré Bioscience, and Theramex — represent a cross-section of the innovation driving this change. From next-generation reproductive longevity programs to microbiome-based immunotherapies, they are advancing platforms and pipelines with the potential to redefine care for millions of women worldwide, whether advancing that mission is an explicit driver for the company or a consequence of a broader scientific approach.
Together, these biotechs are not just developing new treatments, they are helping to close the gender gap in medicine and setting a new standard for how women’s health is defined, studied, and delivered.
Reproductive Health and Fertility
For decades, reproductive innovation focused narrowly on conception, most often through in vitro fertilization (IVF), while other critical issues, such as ovarian aging, declining egg quality, and the health of reproductive microenvironments, received far less attention. This imbalance left women with limited options for preserving fertility, mitigating age-related decline, or addressing conditions that can silently erode reproductive potential.
Today, a new generation of biotechs is expanding the field beyond fertility treatments alone. Harnessing advances in regenerative biology, stem cell and exosome science, reproductive immunology, the microbiome, and targeted molecular therapeutics, these companies are working to extend reproductive health span, improve maternal outcomes, and address conditions across the reproductive continuum. Their innovations aim to reduce the physical and financial burdens of fertility care, develop disease-modifying treatments for pregnancy complications, and introduce non-hormonal options for chronic gynecologic pain, giving women greater control over their reproductive futures at every life stage.
Oviva Therapeutics, Gameto, Freya Biosciences, Comanche Biopharma, and Gynica each bring a distinct but complementary approach — from preserving ovarian function and transforming egg maturation, to restoring healthy reproductive ecosystems, protecting maternal and fetal health, and treating endometriosis — moving reproductive medicine toward a more comprehensive, lifelong model of care.
Oviva Therapeutics
Oviva Therapeutics is pioneering a novel approach in women’s health with its lead program, OVI-586, a recombinant analog of anti-Müllerian hormone (AMH) designed to slow the depletion of the ovarian reserve. AMH is naturally produced by growing ovarian follicles and acts to inhibit the recruitment of additional follicles, thereby helping preserve the finite pool of eggs present from birth. Oviva’s engineered AMH analog enhances this natural regulatory signal, with the goal of maintaining ovarian function, delaying menopause, and extending the number of years women remain in a hormonally balanced state. In preclinical models across multiple species, OVI-586 has demonstrated the ability to synchronize follicle recruitment, conserve the ovarian reserve, and increase the yield of mature oocytes retrieved during fertility treatments, which could be a significant breakthrough for patients with diminished ovarian reserve or poor response to stimulation.
The initial development focus for OVI-586 is as an acute adjunct in IVF for women who are poor responders, where improving the efficiency of ovarian stimulation could meaningfully impact pregnancy outcomes. However, the same mechanism holds promise for longer-term applications, including delaying the onset of menopause, preserving fertility for women undergoing medical treatments that can impair ovarian function, and potentially supporting new contraceptive strategies. By intervening at the earliest stage of follicle recruitment, Oviva’s approach targets a root cause of reproductive aging rather than only addressing downstream hormonal changes.
Founded as a spin-out from Cambrian BioPharma and based on intellectual property licensed from Massachusetts General Hospital, Oviva raised $11.5 million in seed financing in 2022 to advance its AMH platform. In April 2025, the company was acquired by Granata Bio, a U.S. biotech focused on infertility and reproductive medicine. Under Granata’s ownership, OVI-586 is being advanced toward clinical trials with the backing of a broader commercial and development infrastructure, including a strategic collaboration with Gedeon Richter to expand capabilities in fertility therapeutics. Oviva’s work represents an entirely new therapeutic category aimed at reproductive longevity with the potential to redefine the way fertility, menopause, and women’s hormonal health are managed across the lifespan.
Gameto
Gameto is advancing a transformative, cell engineering-based approach to fertility care with its lead product, Fertilo, a platform that uses induced pluripotent stem cell (iPSC)-derived ovarian support cells (OSCs) to mature eggs outside the body. By reconstructing the ovarian microenvironment in vitro, Gameto has significantly reduced the need for prolonged hormone stimulation (from 10–14 days down to just 2–3 days) while delivering outcomes far superior to conventional in vitro maturation (IVM). In a 40-patient cohort study, Fertilo achieved a 70% oocyte maturation rate versus 52% for IVM, produced over fivefold more euploid blastocysts per cycle (10% vs. 2%), and doubled pregnancy rates (44% compared with 20%), with eight out of 10 patients producing at least one viable embryo versus three in the control group. This led to the world’s first live birth using iPSC-derived egg maturation, recorded in Peru in late 2024.
Gameto is now running the first U.S. phase III clinical trial of its kind, under an FDA-cleared IND for Fertilo, enrolling across approximately 15 sites. The randomized, double-blind trial will assess efficacy (pregnancy and live birth rates) and safety in a target population including women with infertility of at least one year. Meanwhile, Fertilo has already gained regulatory approval for clinical use in Australia, Japan, Argentina, Mexico, Paraguay, and Peru, and has a strategic commercialization partnership with IVFAustralia (part of Virtus Health) to expand access within the Asia-Pacific region.
The scientific underpinnings of Fertilo trace back to foundational research at Harvard’s Wyss Institute, where Gameto co-founders leveraged ovarian support cell technology to recreate functional follicular environments in vitro. By licensing this breakthrough and building proprietary OSC lines from clinical-grade iPSCs (licensed from REPROCELL under GMP conditions), Gameto has constructed a scalable, reproducible, and regulatory-aligned system for engineered egg maturation.
On the financial front, Gameto has raised approximately $73 million to date. A $33 million Series B in mid-2024, led by Two Sigma Ventures and RA Capital (with participation from Insight Partners, Future Ventures, and notable female-founded funds), supports clinical development, U.S. phase III enrollment, and global roll-out. In early 2025, Gameto received $10 million in ARPA-H “Launchpad” funding to progress its emerging Ameno program — a cell-based hormone replacement strategy intended to mitigate menopause symptoms by implanting iPSC-derived ovarian organoids.
Freya Biosciences
Freya Biosciences is a clinical-stage biotech reimagining women’s reproductive health by targeting the immune and microbial underpinnings that undermine fertility. At the heart of its innovation is the DYSCOVER™ platform, which leverages microbial immunotherapies, specifically curated Lactobacillus-dominant consortia, to restore a balanced vaginal microbiome, dampen local inflammation, and enhance reproductive outcomes. Research suggests that a dysbiotic vaginal ecosystem — frequently associated with anaerobes like Gardnerella — triggers immune activation linked to IVF failure, miscarriage, endometriosis-related infertility, and preterm birth. By transplanting healthy, engraftable bacterial strains, Freya aims to suppress that inflammation, improving embryo implantation success rates and potentially reducing the risk of complications during pregnancy.
Freya’s lead therapeutic FB301 emerged from its platform as an investigational microbial immunomodulatory product designed for women undergoing assisted reproductive technologies. In early phase I trials, the therapy demonstrated the capacity to shift patients from dysbiosis to Lactobacillus-dominant microbiomes within days. A separate case study involving vaginal microbiota transplant (VMT) from a healthy donor achieved longstanding microbiome stability and resulted in a full-term healthy birth, highlighting the profound potential of this microbial approach.
With its mission firmly grounded in data-driven design, Freya augments its biological approach with a robust multi-omic profiling engine incorporating microbiome sequencing, proteomic immune markers, and transcriptomic data across hundreds of women. This comprehensive dataset accelerates strain selection and allows for precise, next-generation live biotherapeutic products (LBPs).
Financially, Freya has gained significant traction. In late 2023, it raised a $38 million Series A — one of the largest in women’s reproductive health — backed by Sofinnova Partners, OMX Ventures, CE-Ventures, Angelini Ventures, and others. In late 2024, that funding was extended with a $10.4 million strategic investment led by the Bill & Melinda Gates Foundation, supplemented with $1.4 million from Denmark’s Export and Investment Fund; this brought total funding to nearly $50 million. The Gates-backed expansion aims to push Freya’s DYSCOVER™ platform into new indications such as bacterial vaginosis and preterm birth, critical areas of global maternal health.
Rather than positioning itself solely as a fertility company, Freya is building a new therapeutic category at the intersection of microbiology, immunology, and reproductive medicine. By addressing the upstream immune triggers that can derail healthy pregnancies, the company aims to make fertility treatments more effective, reduce miscarriage risk, and improve maternal outcomes on a global scale, especially in underserved settings where access to advanced reproductive care remains limited.
Comanche Biopharma
Comanche Biopharma is a clinical-stage company pioneering the first maternal–fetal therapy to address preeclampsia, a life-threatening hypertensive disorder of pregnancy that affects 5–8% of pregnancies worldwide and is a leading cause of maternal and neonatal mortality. Despite its prevalence and severity, there are no FDA-approved disease-modifying treatments. Current management often centers on premature delivery, which can lead to significant complications for both mother and child.
Comanche’s lead candidate CBP-4888 is designed to address the underlying molecular driver of preeclampsia rather than merely managing symptoms. The therapy leverages RNA interference (RNAi) to silence the gene encoding soluble fms-like tyrosine kinase 1 (sFlt-1), an anti-angiogenic protein implicated in the vascular dysfunction central to preeclampsia pathophysiology. Elevated sFlt-1 disrupts placental blood vessel development, leading to maternal hypertension, proteinuria, and systemic endothelial damage. By reducing circulating sFlt-1 levels, CBP-4888 aims to restore angiogenic balance, improve placental function, and prolong pregnancy safely.
The therapeutic is formulated for targeted delivery to the placenta, minimizing systemic exposure and off-target effects, a critical consideration in pregnancy. This localized approach is intended to maximize efficacy while preserving maternal and fetal safety, addressing one of the greatest hurdles in obstetric drug development. Preclinical studies have demonstrated robust sFlt-1 knockdown, improved maternal blood pressure, and enhanced fetal growth metrics.
CBP-4888 entered phase I clinical testing in 2024 to establish safety, pharmacokinetics, and preliminary biomarker effects in pregnant individuals with early-onset preeclampsia. The company’s development strategy focuses on accelerating timelines through adaptive trial designs, working closely with regulators to address the ethical and logistical complexities of clinical research in pregnancy.
With a mission to prevent unnecessary maternal and neonatal deaths, Comanche Biopharma’s work has the potential to transform preeclampsia management from a reactive to a preventive paradigm. Success could not only save lives but also reduce the long-term health burdens faced by mothers and children affected by premature delivery.
Gynica
Gynica is an Israel-based biopharmaceutical company developing cannabinoid-based therapeutics for gynecological conditions, with an initial focus on endometriosis, a chronic, estrogen-dependent inflammatory disorder that affects an estimated 10% of women of reproductive age worldwide. Endometriosis can cause severe pelvic pain, dysmenorrhea, dyspareunia, and infertility, yet treatment options remain limited to hormonal suppression, surgery, or chronic pain management, approaches that often carry significant side effects or high recurrence rates.
Gynica’s lead program is built on proprietary formulations of cannabinoids, including both naturally occurring and synthetic compounds, designed to selectively modulate the endocannabinoid system (ECS) within gynecologic tissues. The ECS plays a key role in regulating pain perception, inflammation, and tissue remodeling, pathways that are dysregulated in endometriosis. By targeting cannabinoid receptors (CB1 and CB2) and other ECS-related molecular pathways, Gynica aims to reduce chronic inflammation, inhibit aberrant tissue growth, and alleviate pain without the systemic hormonal suppression used in most current therapies.
The company’s scientific program is informed by preclinical research showing that cannabinoids can modulate prostaglandin production, reduce inflammatory cytokine signaling, and influence the neuro-immune crosstalk involved in chronic pelvic pain syndromes. Importantly, Gynica’s approach is designed to be nonhormonal, fertility-preserving, and suitable for long-term use, addressing the needs of patients who either cannot or prefer not to use hormonal therapies.
Gynica is conducting its first-in-human studies in collaboration with Hadassah Medical Center in Jerusalem, leveraging its gynecological research expertise and patient access. Early-phase clinical work focuses on optimizing dosing, delivery routes, and safety profiles for chronic administration, with future programs planned for additional indications such as dysmenorrhea, vulvodynia, and menopausal symptom relief.
By integrating cannabinoid science with rigorous pharmaceutical development standards, Gynica seeks to create a new therapeutic class in women’s health that addresses the underlying biology of gynecologic pain and inflammation, expands non-hormonal treatment choices, and improves quality of life for millions of women worldwide.
Autoimmune and Immune Modulation
Autoimmune diseases are among the most striking examples of gender disparity in health, affecting women at rates up to nine times higher than men in conditions like lupus, rheumatoid arthritis, multiple sclerosis, and Sjögren’s syndrome. Yet for decades, drug development pipelines and clinical trial designs rarely accounted for the biological and hormonal factors that make these diseases more prevalent and often more severe in women. The result has been treatments that can fall short in efficacy, tolerability, or durability for half the patient population.
Today, a new wave of biotech innovation is challenging that status quo. By integrating insights into sex-specific immune responses, hormonal influences, and genetic predispositions, these companies are engineering therapies that directly address the complex drivers of autoimmunity in women. Their approaches span dual-targeting biologics that act on both B and T cells, microbiome-based interventions that aim to restore immune balance, and small molecules that precisely recalibrate inflammatory signaling. These approaches go beyond merely symptom control to shift the trajectory of disease, improve quality of life, and deliver solutions designed from the ground up with women’s biology in mind.
Fab Biopharma
Fab Biopharma is developing a new class of biologics designed to address the multifaceted immune dysfunction underlying many autoimmune diseases, with a particular focus on conditions that disproportionately affect women, such as lupus and Sjögren’s syndrome. The company’s approach centers on dual-targeting biologics that simultaneously modulate both B cells and T cells — the two primary arms of the adaptive immune system. This strategy recognizes that in complex autoimmune diseases, pathogenic antibodies produced by B cells often act in concert with aberrantly activated T cells to sustain chronic inflammation and tissue damage. By addressing both pathways at once, Fab Biopharma aims to achieve deeper and more durable disease control than therapies that focus on a single immune cell type.
At the core of Fab’s platform is a suite of engineered antibody constructs that combine precision targeting of surface markers with built-in immunomodulatory functions. These dual-acting biologics can selectively deplete or reprogram autoreactive B cells while simultaneously dampening the activity of pathogenic T cell subsets, such as TH17 cells, that drive inflammatory cascades. Early preclinical work has demonstrated the potential to not only reduce disease activity but to induce longer-term immune tolerance — a key goal in autoimmune therapy, where remission without continuous immunosuppression remains rare.
Lupus and Sjögren’s syndrome, two of Fab’s lead indications, are especially challenging to treat due to their systemic nature, fluctuating disease activity, and diverse organ involvement. In lupus, autoreactive B cells produce a wide spectrum of pathogenic autoantibodies, while dysregulated T cell activity exacerbates tissue injury. In Sjögren’s, chronic immune attack on exocrine glands leads to debilitating dryness, fatigue, and multi-organ symptoms, with few disease-modifying options currently available. Fab’s candidates are being designed to address both the antibody-mediated and T cell–driven aspects of these diseases, potentially offering more comprehensive symptom relief and long-term disease control.
In addition to its scientific innovation, Fab Biopharma is building a development strategy that incorporates lessons from past autoimmune drug failures, including the need for biomarker-driven patient selection and adaptive trial designs that can capture the heterogeneity of these diseases. The company has secured significant venture funding to advance its lead programs toward the clinic and is actively building partnerships with academic centers and patient advocacy organizations to ensure that trial designs reflect the real-world needs of women living with these conditions. By combining a mechanistically sophisticated therapeutic approach with a patient-centered development philosophy, Fab Biopharma is positioning itself as a next-generation leader in autoimmune disease treatment.
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is a biopharmaceutical company advancing targeted therapies for autoimmune diseases with high unmet need, particularly those that disproportionately affect women. Its flagship product LUPKYNIS® (voclosporin) is the first FDA-approved oral therapy specifically indicated for lupus nephritis, a severe and potentially life-threatening complication of systemic lupus erythematosus (SLE). Lupus itself affects women at rates up to nine times higher than men, often striking during their prime reproductive years, and lupus nephritis remains a leading cause of kidney failure in this population.
LUPKYNIS is a next-generation calcineurin inhibitor designed to improve both efficacy and safety over legacy agents. In pivotal phase III trials, the therapy, when combined with standard-of-care mycophenolate mofetil and low-dose steroids, more than doubled the complete renal response rate compared with standard treatment alone, while also accelerating proteinuria reduction. These clinical outcomes are particularly meaningful for women, as early and sustained renal response can preserve long-term kidney function, reduce hospitalizations, and improve quality of life.
Beyond its commercial success with LUPKYNIS, Aurinia is advancing a pipeline that includes AUR200 (ritinercept), a dual BAFF/APRIL antagonist designed to modulate B cell activity and autoantibody production without broadly suppressing the immune system. This mechanism holds potential not only in lupus but also across a range of chronic autoimmune diseases with female-skewed prevalence. The company’s strategic focus reflects a commitment to precision immune modulation, targeting the underlying drivers of disease while minimizing systemic toxicity.
With its combination of a first-in-class approved product, a pipeline aimed at expanding therapeutic options, and a patient population deeply impacted by health inequities, Aurinia is positioned as both a commercial leader and an innovator in autoimmune health. Its work is redefining standards of care in lupus nephritis and beyond, offering therapies that are as much about protecting long-term health as they are about delivering measurable clinical gains today.
Aclaris Therapeutics
Aclaris Therapeutics is developing a portfolio of small molecule immunomodulators with a focus on kinase inhibition, targeting pathways that play a central role in autoimmune and inflammatory diseases, many of which disproportionately affect women. Two key signaling cascades underlie much of the company’s pipeline: the Janus kinase (JAK) pathway, which mediates cytokine signaling and drives numerous immune cell functions, and the mitogen-activated protein kinase (MAPK) pathway, which regulates inflammatory gene expression and immune cell activation. Dysregulation in these pathways is implicated in conditions such as rheumatoid arthritis, systemic lupus erythematosus, and alopecia areata, diseases where women represent the majority of patients and face significant unmet treatment needs.
Aclaris’ clinical and preclinical programs include both covalent and reversible inhibitors, designed to achieve high selectivity and minimize off-target effects. For example, its lead covalent JAK3 inhibitor is engineered to bind irreversibly to a unique cysteine residue in the enzyme’s ATP-binding pocket, offering greater precision and potentially reducing the broader immunosuppressive effects seen with pan-JAK inhibition. Similarly, its MAPK pathway inhibitors focus on upstream kinases like MK2 (MAPK-activated protein kinase 2), a critical node in the production of pro-inflammatory cytokines, such as TNF-α and IL-6. By modulating these targets, Aclaris aims to quell inflammatory cascades while preserving protective immune function.
The company’s work in alopecia areata — a chronic autoimmune disorder that causes hair loss — is particularly noteworthy. This condition has a higher prevalence in women and can carry profound psychosocial burdens. In phase II trials, Aclaris’ oral JAK inhibitors have demonstrated the ability to promote hair regrowth by interrupting the autoimmune attack on hair follicles, and ongoing studies are evaluating durability of response and long-term safety. Beyond dermatology, Aclaris is applying its kinase expertise to systemic autoimmune diseases, such as rheumatoid arthritis and lupus, aiming for oral, targeted therapies that could reduce reliance on biologics or broad-spectrum steroids.
From a strategic standpoint, Aclaris benefits from a diversified approach: its dermatology programs target niche but high-impact indications with clearer regulatory pathways, while its systemic autoimmune efforts address larger, more competitive markets. The company has maintained a disciplined capital allocation strategy, advancing its lead candidates into proof-of-concept trials while leveraging partnerships to share development risk. For women living with autoimmune conditions that are often underdiagnosed, undertreated, or complicated by gender-specific immune biology, Aclaris’ precision kinase inhibitors could represent a new generation of targeted, well-tolerated therapies.
Broader Women’s Health and Longevity
Women’s health is a lifelong continuum, yet for much of modern medical history, research and innovation have concentrated on only a fraction of that journey — often the reproductive years —leaving critical gaps in prevention, wellness, and healthy aging. The emerging field of broader women’s health and longevity is stepping in to close those gaps, developing solutions that safeguard physical vitality, cognitive clarity, hormonal balance, and metabolic resilience from adolescence through post-menopause and well into later life.
This work is especially urgent now, as demographic shifts, regulatory momentum, and growing investment in femtech create a rare opportunity to redefine how women’s health is supported across decades. Leaders in this space are reimagining contraception and infection prevention with non-hormonal, user-centered innovations, while others are translating breakthroughs in epigenetics and aging science into personalized, measurable strategies to slow or reverse biological aging, often tailoring interventions to the unique hormonal and metabolic changes women experience over time.
The companies featured here — Daré Bioscience and Theramex — are setting a new standard for what it means to “age well” as a woman, building tools that are not only more effective but also more empowering, equitable, and attuned to women’s lived realities.
Daré Bioscience
San Diego–based Daré Bioscience is dedicated to advancing women’s health across the full spectrum of reproductive and sexual wellness, with a pipeline that spans contraception, fertility, menopause, vaginal and sexual health, and hormone-free therapeutic alternatives. The company’s strategy centers on identifying areas of high unmet need in women’s health that have historically received limited innovation, then developing novel products that can be readily integrated into clinical practice and women’s daily lives.
Daré’s portfolio includes multiple late- and mid-stage programs. In contraception, the company is developing Ovaprene, a first-in-class, non-hormonal monthly vaginal ring now in phase III studies, and ADA-1402, a next-generation hormone-free candidate in preclinical development. In menopause and genitourinary syndrome of menopause (GSM), Daré is advancing Dare-VVA1, a topical, hormone-free treatment for vulvovaginal atrophy designed to address dryness, discomfort, and sexual pain without systemic estrogen exposure. The company is also pursuing Dare-PDM1, a hormone-free candidate for primary dysmenorrhea, and Dare-LARC1, an innovative long-acting reversible contraceptive.
In sexual health, Daré is pioneering Dare-PTB1 for the treatment of hypoactive sexual desire disorder (HSDD) and other sexual arousal disorders, aiming to offer non-invasive, on-demand options for conditions that significantly impact quality of life yet remain underserved. Additionally, Daré is progressing Dare-BV1, a single-dose intravaginal therapy for bacterial vaginosis that has demonstrated high cure rates in pivotal trials, with the potential to improve adherence and reduce recurrence.
By advancing a diversified pipeline that addresses both preventive and therapeutic needs, Daré Bioscience aims to broaden women’s options at every stage of reproductive life. Its programs target not only contraception and fertility but also the management of menopausal symptoms, sexual dysfunction, and vaginal infections, reflecting a commitment to creating practical, accessible solutions that empower women to take charge of their health.
Theramex
Theramex is a global pharmaceutical company dedicated exclusively to women’s health, delivering innovative therapies that support women across all stages of life, from reproductive years to postmenopause. With a portfolio spanning fertility, contraception, menopause management, and postmenopausal osteoporosis, Theramex addresses both acute and long-term health needs, reflecting a comprehensive approach to women’s well-being and longevity.
In fertility, Theramex offers recombinant follicle-stimulating hormone (FSH) and other hormone therapies to support assisted reproductive technologies, helping women and couples navigate infertility with clinically proven options. Its contraception line includes both hormonal and non-hormonal choices designed for convenience, efficacy, and safety, recognizing the diverse needs and preferences of women worldwide.
For menopause, Theramex has developed and commercialized hormone replacement therapies that target both vasomotor symptoms and genitourinary syndrome of menopause, aiming to restore quality of life while supporting longer-term health. Notably, products like Bijuva, a bioidentical estradiol and progesterone combination, provide a regulated, standardized alternative to compounded hormones. In bone health, Theramex markets anabolic and antiresorptive treatments such as Livogiva (teriparatide) to address osteoporosis, which disproportionately affects women after menopause and is a major driver of morbidity in later life.
Theramex’s strategy combines in-licensed products from innovative biotech partners with internally driven life-cycle management, enabling rapid access to novel therapies across more than 80 countries. The company invests in educational programs and patient outreach to close awareness gaps around underdiagnosed or undertreated conditions like osteoporosis and menopause-related cardiovascular risk.
By uniting reproductive health, preventive care, and healthy aging under one umbrella, Theramex represents a longevity-focused model in women’s health, addressing not just isolated conditions but the interconnected physiological changes that shape a woman’s life course.
